|
Virtual Meetings 2020
Meet The Professor: Management of Multiple Myeloma![]() For more information, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153. Each 1-hour session will include 3 topic modules focused on current management, emerging research and novel agents and strategies under active investigation for MM. Each event will employ an identical format that will include the following elements:
Target Audience Learning Objectives
Physician Competencies To Be Addressed
CME Credit Form Contact Information Accreditation Statement USF Health designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. ![]() American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology. Privacy Disclosure Completion Requirements Disclaimer Equal Opportunity Statement Content Validation and Disclosures STEERING COMMITTEE — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Kenneth C Anderson, MD Advisory Committee: Bristol-Myers Squibb Company, Gilead Sciences Inc, Janssen Biotech Inc, Sanofi Genzyme, Takeda Oncology; Consulting Agreements: Amgen Inc, Pfizer Inc, Precision BioSciences, Sumitomo Dainippon Pharma Oncology Inc; Ownership Interest: Scientific founder of C4 Therapeutics and OncoPep. Rafael Fonseca, MD Advisory Committee: Adaptive Biotechnologies Corporation, ONCOtracker Inc; Consulting Agreements: AbbVie Inc, Aduro Biotech, Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Merck, Novartis, ONCOtracker Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi Genzyme, Takeda Oncology. Morie A Gertz, MD, MACP Advisory Board: Ionis Pharmaceuticals; Consulting Agreements: Akcea Therapeutics, Alnylam Pharmaceuticals Inc, Prothena; Data and Safety Monitoring Board/Committee: AbbVie Inc, Celgene Corporation; Honoraria: Akcea Therapeutics, Ambry Genetics, Amgen Inc, Janssen Biotech Inc, Celgene Corporation, Karyopharm Therapeutics, Pfizer Inc (to Institution), Sanofi Genzyme; Stock Options: Aurora Biopharma. Irene M Ghobrial, MD Accommodations: Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Novartis, Takeda Oncology; Advisory Committee and Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cellectar Biosciences Inc, GlaxoSmithKline, Novartis, Sanofi Genzyme, Takeda Oncology; Speakers Bureau: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Takeda Oncology. Sergio A Giralt, MD Scientific Advisory Board: Actinium Pharmaceuticals Inc, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Omeros, Pfizer Inc, Sanofi Genzyme; Research Support: Actinium Pharmaceuticals Inc, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Pfizer Inc, Sanofi Genzyme. Jonathan L Kaufman, MD Consulting Agreements: Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Janssen Biotech Inc, Tecnofarma; Contracted Research: Amgen Inc, Bristol-Myers Squibb Company, Fortis Therapeutics, Janssen Biotech Inc, Sutro Biopharma; Data and Safety Monitoring Board/Committee: TG Therapeutics Inc. Shaji K Kumar, MD Advisory Committee: AbbVie Inc, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Takeda Oncology; Consulting Agreements: AbbVie Inc, Amgen Inc, Celgene Corporation, Cellectar Biosciences Inc, GeneCentrix Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Molecular Partners, Oncopeptides, Takeda Oncology; Contracted Research (to Institution): AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, CARsgen Therapeutics, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Takeda Oncology, TeneoBio. Ola Landgren, MD, PhD Consulting Agreements and Speakers Bureau: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc; Contracted Research: Amgen Inc, Janssen Biotech Inc, Takeda Oncology; Data and Safety Monitoring Board/Committee: Janssen Biotech Inc, Merck, Takeda Oncology, Theradex Oncology. Sagar Lonial, MD Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Takeda Oncology; Contracted Research: Celgene Corporation, Janssen Biotech Inc, Takeda Oncology. Joseph Mikhael, MD Consulting Agreements: Amgen Inc, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Karyopharm Therapeutics, Sanofi Genzyme, Takeda Oncology. Nikhil C Munshi, MD Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Amgen Inc, BeiGene, Bristol-Myers Squibb Company, Janssen Biotech Inc, Karyopharm Therapeutics, OncoPep, Takeda Oncology; Ownership Interest: OncoPep. Robert Z Orlowski, MD, PhD Advisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, EcoR1 Capital LLC, FORMA Therapeutics, Genzyme Corporation, GlaxoSmithKline, Ionis Pharmaceuticals Inc, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Legend Biotech, Molecular Partners, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Servier, Takeda Pharmaceuticals North America Inc; Consulting Agreement: STATinMED; Contracted Research: BioTheryX Inc, CARsgen Therapeutics, Celgene Corporation, Exelixis Inc, Janssen Biotech Inc, Sanofi Genzyme, Takeda Pharmaceuticals North America Inc; Ownership Interest: Asylia Therapeutics Inc (founder, patents, equity). Krina K Patel, MD, MSc Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Nektar, Precision BioSciences, Takeda Oncology; Consulting Agreement: Pfizer Inc; Contracted Research: AbbVie Inc, Allogene Therapeutics, Bristol-Myers Squibb Company, Celgene Corporation, Cellectis, Janssen Biotech Inc, Nektar, Poseida Therapeutics, Precision BioSciences, Takeda Oncology. Noopur Raje, MD Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Novartis, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology; Contracted Research: AstraZeneca Pharmaceuticals LP, Lilly. S Vincent Rajkumar, MD Nina Shah, MD Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, GlaxoSmithKline, Indapta Therapeutics, Karyopharm Therapeutics, Nektar, Oncopeptides, Precision BioSciences, Sanofi Genzyme, Seagen Inc, Surface Oncology; Ownership Interest: Indapta Therapeutics; Contracted Research: bluebird bio, Celgene Corporation, Janssen Biotech Inc, Sutro Biopharma, TeneoBio. A Keith Stewart, MB, ChB Advisory Committee: Amgen Inc, GlaxoSmithKline, Janssen Biotech Inc; Consulting Agreements: Amgen Inc, GlaxoSmithKline, Janssen Biotech Inc, Oncopeptides; Data and Safety Monitoring Board/Committee: Oncopeptides. Peter Voorhees, MD Advisory Committee: AbbVie Inc, Bristol-Myers Squibb Company; Consulting Agreements: GlaxoSmithKline, Novartis, Oncopeptides; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company. CONTRIBUTING ONCOLOGISTS — The following contributors (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Spencer Henick Bachow, MD Warren S Brenner, MD Speakers Bureau: Celgene Corporation, Takeda Oncology. Gigi Chen, MD Lyle Feinstein, MD Maria Regina Flores, MD Ranju Gupta, MD Speakers Bureau: Lilly. Atif Hussein, MD, MMM Sulfi Ibrahim, MD Zanetta S Lamar, MD Laurie Matt-Amaral, MD, MPH Speakers Bureau: Bristol-Myers Squibb Company. Neil Morganstein, MD Benjamin Parsons, DO Shachar Peles, MD Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, TG Therapeutics Inc, Verastem Inc; Speakers Bureau: Janssen Biotech Inc, Takeda Oncology. Erik J Rupard, MD Syed Farhan Zafar, MD PROJECT CHAIR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc. USF HEALTH CPD STAFF, RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — No relevant conflicts of interest to disclose. Commercial SupportThese activities are supported by educational grants from Adaptive Biotechnologies Corporation, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Takeda Oncology. |